Should I buy or sell Bio-Rad Laboratories stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Rad Laboratories in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BIO shares. View BIO analyst ratings or view top-rated stocks .

What is Bio-Rad Laboratories' stock price target for 2024?

5 analysts have issued 1 year target prices for Bio-Rad Laboratories' stock. Their BIO share price targets range from $365.00 to $550.00. On average, they expect the company's share price to reach $468.00 in the next twelve months. This suggests a possible upside of 55.8% from the stock's current price. View analysts price targets for BIO or view top-rated stocks among Wall Street analysts .

How have BIO shares performed in 2024?

Bio-Rad Laboratories' stock was trading at $322.89 on January 1st, 2024. Since then, BIO stock has decreased by 7.0% and is now trading at $300.41. View the best growth stocks for 2024 here .

Are investors shorting Bio-Rad Laboratories?

Bio-Rad Laboratories saw a increase in short interest in March. As of March 15th, there was short interest totaling 579,300 shares, an increase of 15.1% from the February 29th total of 503,400 shares. Based on an average trading volume of 197,700 shares, the days-to-cover ratio is currently 2.9 days. Approximately 2.9% of the company's stock are short sold. View Bio-Rad Laboratories' Short Interest .

When is Bio-Rad Laboratories' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our BIO earnings forecast .

How were Bio-Rad Laboratories' earnings last quarter?

Bio-Rad Laboratories, Inc. (NYSE:BIO) issued its quarterly earnings results on Thursday, February, 15th. The medical research company reported $3.10 earnings per share for the quarter, topping analysts' consensus estimates of $2.93 by $0.17. The medical research company had revenue of $681.18 million for the quarter, compared to the consensus estimate of $685 million. Bio-Rad Laboratories had a negative net margin of 23.86% and a positive trailing twelve-month return on equity of 3.90%. The company's revenue was down 6.7% on a year-over-year basis. During the same quarter last year, the company earned $3.31 EPS. Read the conference call transcript .

What ETFs hold Bio-Rad Laboratories' stock?

ETFs with the largest weight of Bio-Rad Laboratories (NYSE:BIO) stock in their portfolio include Putnam BioRevolution ETF (SYNB) , Amplify Treatments, Testing and Advancements ETF (GERM) , Principal Healthcare Innovators ETF (BTEC) , Invesco S&P 500 Equal Weight Health Care ETF (RSPH) , ROBO Global Healthcare Technology and Innovation ETF (HTEC) , Invesco S&P 500 Equal Weight Health Care ETF (RYH) , First Trust Indxx Medical Devices ETF (MDEV) and QRAFT AI-Enhanced U.S. Next Value ETF (NVQ) .

What guidance has Bio-Rad Laboratories issued on next quarter's earnings?

Bio-Rad Laboratories updated its FY 2024 earnings guidance on Friday, February, 16th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.7 billion-$2.7 billion, compared to the consensus revenue estimate of $2.7 billion.

What is Norman Schwartz's approval rating as Bio-Rad Laboratories' CEO?

325 employees have rated Bio-Rad Laboratories Chief Executive Officer Norman Schwartz on Glassdoor.com . Norman Schwartz has an approval rating of 84% among the company's employees.

What other stocks do shareholders of Bio-Rad Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Rad Laboratories investors own include BioMarin Pharmaceutical (BMRN) , Incyte (INCY) , Puma Biotechnology (PBYI) , AbbVie (ABBV) , NVIDIA (NVDA) , Broadcom (AVGO) , Johnson & Johnson (JNJ) , Advanced Micro Devices (AMD) , Alibaba Group (BABA) and Intel (INTC) .

Who are Bio-Rad Laboratories' major shareholders?

Bio-Rad Laboratories' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Polianta Ltd (0.01%), Park Avenue Securities LLC (0.01%), First Hawaiian Bank (0.01%), Insight Wealth Strategies LLC (0.00%), Fulton Bank N.A. (0.00%) and Ballentine Partners LLC (0.00%). Insiders that own company stock include Ajit Ramalingam , Annette Tumolo , Dara Wright, Ilan Daskal , Michael Crowley , Timothy S Ernst and Timothy S Ernst . View institutional ownership trends .

How do I buy shares of Bio-Rad Laboratories?

Shares of BIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Bio-Rad Laboratories have any subsidiaries?

The following companies are subsidiares of Bio-Rad Laboratories: (f/k/a Bio-Rad Laboratories (Israel) Inc.), BIO-RAD spol. s r.o., Bio-Metrics (U.K.) Limited, Bio-Rad, Bio-Rad (Shanghai) Life Science Research & Development Co. Ltd., Bio-Rad 1, Bio-Rad AbD Serotec GmbH, Bio-Rad AbD Serotec Ltd, Bio-Rad China Ltd., Bio-Rad Denmark ApS, Bio-Rad Europe GmbH, Bio-Rad Export LLC, Bio-Rad Finland Oy (f/k/a DiaMed Fennica Oy), Bio-Rad France, Bio-Rad France Holding, Bio-Rad Germany Holding GmbH, Bio-Rad Haifa Ltd., Bio-Rad Holdings LLC, Bio-Rad Hungary Trading LLC, Bio-Rad IHC Europe GmbH, Bio-Rad Innovations, Bio-Rad Korea Ltd., Bio-Rad Laboratories (Canada) Limited, Bio-Rad Laboratories (India) Private Limited, Bio-Rad Laboratories (Pty) Ltd, Bio-Rad Laboratories (Rishon) Inc., Bio-Rad Laboratories (Shanghai) Co. Ltd., Bio-Rad Laboratories (Singapore) Pte Ltd, Bio-Rad Laboratories AB, Bio-Rad Laboratories AG, Bio-Rad Laboratories B.V., Bio-Rad Laboratories Ges.m.b.H., Bio-Rad Laboratories GmbH, Bio-Rad Laboratories K.K., Bio-Rad Laboratories Limited, Bio-Rad Laboratories Logistik GmbH, Bio-Rad Laboratories Ltd., Bio-Rad Laboratories M.EPE, Bio-Rad Laboratories NV, Bio-Rad Laboratories Pty Ltd, Bio-Rad Laboratories S.A., Bio-Rad Laboratories S.r.l., Bio-Rad Laboratories SAS, Bio-Rad Laboratories-Aparelhos e Reagentes para Laboratórios Lda, Bio-Rad Laboratorii OOO, Bio-Rad Laboratórios Brasil Ltda., Bio-Rad Luxembourg S.à r.l., Bio-Rad Medical Diagnostics GmbH, Bio-Rad Middle East FZ-LLC, Bio-Rad Norway AS, Bio-Rad Pacific Limited, Bio-Rad Pasteur, Bio-Rad Polska Sp. z o.o., Bio-Rad QL Inc., Bio-Rad S.A., Bio-Rad Services France, Bio-Rad Services UK Limited, Biotest - Businesses, Blackhawk Biosystems, Bridger Technologies Inc., Celsee, Ciphergen Biosystems - ProteinChip Systems Business, DiaMed (G.B.) Ltd, DiaMed (Schweiz) GmbH, DiaMed Benelux NV, DiaMed Diagnostika Deutschland GmbH, DiaMed France SA, DiaMed GmbH, DiaMed Holding AG, DiaMed Holding GmbH, DiaMed Latino-América S.A., DiaMed S.E.A. Limited, DiaMed Österreich GmbH, Distribudora de Analítica para la Medicina Ibérica S.A.U., Dropworks Inc., GnuBIO Inc., Helix Diagnostics, IMV Medical Information Division Inc., International Marketing Ventures Ltd., MJ GeneWorks, Propel Labs - Cell Sorting System Division, QuantaLife, Quantase Ltd., Raindance Technologies Limited, Raindance Techologies Inc., Research Specialties for Laboratories NV, Respiratory Diagnostics Inc., and Wuxi BioCanal Nano Technology Co. Ltd.. Read More

NYSE:BIO

Bio-Rad Laboratories (BIO) Stock Price, News & Analysis

→ Nerd Investor Reveals Secret To Make Money With A.I. (From InvestorPlace) (Ad)

Free BIO Stock Alerts

$300.41

-0.04 (-0.01%)

(As of 04/15/2024 ET)

Compare

Today's Range: $297.72
▼
$305.77
50-Day Range: $300.41
▼
$351.99
52-Week Range: $261.59
▼
$489.36

Volume: 167,913 shs
Average Volume: 199,128 shs
Market Capitalization: $8.57 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $468.00

Get Bio-Rad Laboratories alerts:

Bio-Rad Laboratories MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 55.8% Upside
$468.00 Price Target
Short Interest: Healthy
2.87% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.54
Upright™ Environmental Score
News Sentiment: 0.46
Based on 7 Articles This Week
Insider Trading: Selling Shares
$1.01 M Sold Last Quarter
Proj. Earnings Growth: 11.82%
From $10.41 to $11.64 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.69 out of 5 stars

Medical Sector

64th out of 928 stocks

Analytical Instruments Industry

3rd out of 28 stocks

3.4

Analyst's Opinion

Consensus Rating
Bio-Rad Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Bio-Rad Laboratories has only been the subject of 3 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
2.87% of the float of Bio-Rad Laboratories has been sold short.
Short Interest Ratio / Days to Cover
Bio-Rad Laboratories has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Bio-Rad Laboratories has recently decreased by 2.50%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Bio-Rad Laboratories does not currently pay a dividend.
Dividend Growth
Bio-Rad Laboratories does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Bio-Rad Laboratories has received a 60.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Biochemical assay kits", "PCR machines", "Laboratory reagents", and "Protein gels" products. See details.
Environmental Sustainability
The Environmental Impact score for Bio-Rad Laboratories is -1.54.

1.9

News and Social Media Coverage

News Sentiment
Bio-Rad Laboratories has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Bio-Rad Laboratories this week, compared to 6 articles on an average week.
Search Interest
Only 12 people have searched for BIO on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
MarketBeat Follows
Only 7 people have added Bio-Rad Laboratories to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bio-Rad Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,008,000.00 in company stock.
Percentage Held by Insiders
17.50% of the stock of Bio-Rad Laboratories is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
65.24% of the stock of Bio-Rad Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Bio-Rad Laboratories are expected to grow by 11.82% in the coming year, from $10.41 to $11.64 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bio-Rad Laboratories is -13.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bio-Rad Laboratories is -13.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Bio-Rad Laboratories has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

Nerd Investor Reveals Secret To Make Money With A.I.

He's doing something he's never done before. In ten years, this nerd investor has picked 210+ stocks that have gone up at least 100%.

>>Check out what this A.I. Perfect Storm is<<

About Bio-Rad Laboratories Stock (NYSE:BIO)

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

BIO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BIO Stock News Headlines

April 11, 2024 | marketwatch.com

Oncocyte, Bio-Rad Partner on Global Launch of Transplant Assay

April 11, 2024 | seekingalpha.com

Oncocyte stock rallies 90% post-market on Bio-Rad partnership

April 16, 2024 | InvestorPlace (Ad)

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

April 10, 2024 | businesswire.com

Bio-Rad's Chief Operating Officer Andrew Last to Retire

April 8, 2024 | americanbankingnews.com

Bio-Rad Laboratories, Inc. (NYSE:BIO) Receives Average Recommendation of "Moderate Buy" from Analysts

April 7, 2024 | americanbankingnews.com

StockNews.com Downgrades Bio-Rad Laboratories (NYSE:BIO) to Hold

April 3, 2024 | finance.yahoo.com

Global Clinical Microbiology Market Size To Worth USD 6.58 Billion By 2033 | CAGR of 4.49%

April 3, 2024 | msn.com

Stocks Waver on Higher Bond Yields Ahead of Fed Chair Powell

April 16, 2024 | InvestorPlace (Ad)

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

March 31, 2024 | finance.yahoo.com

25 Countries with Highest Malaria Death Rates

March 28, 2024 | finance.yahoo.com

Global Adult Hemoglobinopathy Testing Market to Reach $513.7 Million by 2030

March 21, 2024 | marketwatch.com

Bio-Rad Names Roop Lakkaraju Chief Financial Officer

March 18, 2024 | markets.businessinsider.com

Thermo Fisher: Hold Rating Justified Amid Modest Growth Prospects and Full Valuation

March 17, 2024 | finance.yahoo.com

BIO Apr 2024 340.000 call

March 14, 2024 | finanznachrichten.de

Laser Capture Microdissection Market Worth $306 million | MarketsandMarkets

March 12, 2024 | uk.finance.yahoo.com

Global Syndromic Multiplex Panels Market Set for Rapid Expansion, Reveals New 2024-2028 Sector Forecast

March 12, 2024 | finanznachrichten.de

Gene Expression Analysis Market Worth $6.2 billion | MarketsandMarkets

March 12, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Maravai Lifesciences Holdings (MRVI) and R1 RCM (RCM)

March 11, 2024 | finance.yahoo.com

Global DNA Diagnostics Market Size To Worth USD 60.5 Billion By 2033 | CAGR Of 9.20%

March 1, 2024 | finance.yahoo.com

Insider Sell: EVP, General Counsel & Secretary Timothy Ernst Sells 2,500 Shares of Bio-Rad ...

February 20, 2024 | finance.yahoo.com

BIO Jun 2024 390.000 put

February 20, 2024 | finance.yahoo.com

BIO Jun 2024 380.000 call

February 20, 2024 | finance.yahoo.com

BIO Jun 2024 290.000 put

February 18, 2024 | seekingalpha.com

Bio-Rad Laboratories, Inc. (BIO) Q4 2023 Earnings Call Transcript

February 17, 2024 | finance.yahoo.com

BIO Mar 2024 550.000 call

February 15, 2024 | reuters.com

Bio Rad Labs rises after posting upbeat fourth-quarter profit

February 15, 2024 | benzinga.com

Bio-Rad Laboratories: Q4 Earnings Insights

See More Headlines

Receive BIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Rad Laboratories and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/15/2024
Today: 4/15/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Analytical instruments
Sub-Industry: Life Sciences Tools & Services
Current Symbol: NYSE:BIO
CUSIP: 09057220
CIK: 12208
Web: www.bio-rad.com
Phone: (510) 724-7000
Fax: 510-741-5817
Employees: 8,030
Year Founded: 1952

Price Target and Rating

Average Stock Price Target: $468.00
High Stock Price Target: $550.00
Low Stock Price Target: $365.00
Potential Upside/Downside: +55.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($21.49)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 28.86
P/E Growth: N/A
Net Income: $-637,320,000.00
Net Margins: -23.86%
Pretax Margin: -31.82%
Return on Equity: 3.90%
Return on Assets: 2.77%

Debt

Debt-to-Equity Ratio: 0.14
Current Ratio: 5.83
Quick Ratio: 4.34

Sales & Book Value

Annual Sales: $2.67 billion
Price / Sales: 3.21
Cash Flow: $12.10 per share
Price / Cash Flow: 24.82
Book Value: $306.51 per share
Price / Book: 0.98

Miscellaneous

Outstanding Shares: 28,520,000
Free Float: 23,527,000
Market Cap: $8.57 billion
Optionable: Optionable
Beta: 0.87

Social Links

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Norman D. Schwartz (Age 74)
Chairman, CEO, President & Principal Financial Officer
Comp: $2.13M
Dr. Andrew J. Last Ph.D. (Age 64)
Executive VP & COO
Comp: $1.12M
Dr. Simon May
Executive VP & President of the Life Science Group
Ms. Tania DeVilliers (Age 51)
Senior Director, Corporate Controller & Interim Principal Accounting Officer
Mr. Yong Chung
Vice President of Investor Relations
Mr. Timothy S. Ernst (Age 64)
Executive VP, General Counsel & Secretary
Matthew Werner
Senior Vice President and Chief Compliance & Privacy Officer
Colleen Corey
Executive Vice President of Global Human Resources
Mr. Michael Crowley (Age 62)
Executive Vice President of Global Commercial Operations
Comp: $974.94k
Lee Boyd
Senior Vice President of Global Commercial Operations - Asia Pacific

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BIO Stock Analysis - Frequently Asked Questions

Should I buy or sell Bio-Rad Laboratories stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Rad Laboratories in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BIO shares.
View BIO analyst ratings or view top-rated stocks.
What is Bio-Rad Laboratories' stock price target for 2024?: 5 analysts have issued 1 year target prices for Bio-Rad Laboratories' stock. Their BIO share price targets range from $365.00 to $550.00. On average, they expect the company's share price to reach $468.00 in the next twelve months. This suggests a possible upside of 55.8% from the stock's current price.
View analysts price targets for BIO or view top-rated stocks among Wall Street analysts.
How have BIO shares performed in 2024?: Bio-Rad Laboratories' stock was trading at $322.89 on January 1st, 2024. Since then, BIO stock has decreased by 7.0% and is now trading at $300.41.
View the best growth stocks for 2024 here.
Are investors shorting Bio-Rad Laboratories?: Bio-Rad Laboratories saw a increase in short interest in March. As of March 15th, there was short interest totaling 579,300 shares, an increase of 15.1% from the February 29th total of 503,400 shares. Based on an average trading volume of 197,700 shares, the days-to-cover ratio is currently 2.9 days. Approximately 2.9% of the company's stock are short sold.
View Bio-Rad Laboratories' Short Interest.
When is Bio-Rad Laboratories' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our BIO earnings forecast.
How were Bio-Rad Laboratories' earnings last quarter?: Bio-Rad Laboratories, Inc. (NYSE:BIO) issued its quarterly earnings results on Thursday, February, 15th. The medical research company reported $3.10 earnings per share for the quarter, topping analysts' consensus estimates of $2.93 by $0.17. The medical research company had revenue of $681.18 million for the quarter, compared to the consensus estimate of $685 million. Bio-Rad Laboratories had a negative net margin of 23.86% and a positive trailing twelve-month return on equity of 3.90%. The company's revenue was down 6.7% on a year-over-year basis. During the same quarter last year, the company earned $3.31 EPS.
Read the conference call transcript.
What ETFs hold Bio-Rad Laboratories' stock?: ETFs with the largest weight of Bio-Rad Laboratories (NYSE:BIO) stock in their portfolio include Putnam BioRevolution ETF (SYNB), Amplify Treatments, Testing and Advancements ETF (GERM), Principal Healthcare Innovators ETF (BTEC), Invesco S&P 500 Equal Weight Health Care ETF (RSPH), ROBO Global Healthcare Technology and Innovation ETF (HTEC), Invesco S&P 500 Equal Weight Health Care ETF (RYH), First Trust Indxx Medical Devices ETF (MDEV) and QRAFT AI-Enhanced U.S. Next Value ETF (NVQ).

What guidance has Bio-Rad Laboratories issued on next quarter's earnings?: Bio-Rad Laboratories updated its FY 2024 earnings guidance on Friday, February, 16th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.7 billion-$2.7 billion, compared to the consensus revenue estimate of $2.7 billion.
What is Norman Schwartz's approval rating as Bio-Rad Laboratories' CEO?: 325 employees have rated Bio-Rad Laboratories Chief Executive Officer Norman Schwartz on Glassdoor.com. Norman Schwartz has an approval rating of 84% among the company's employees.
What other stocks do shareholders of Bio-Rad Laboratories own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Rad Laboratories investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AbbVie (ABBV), NVIDIA (NVDA), Broadcom (AVGO), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), Alibaba Group (BABA) and Intel (INTC).
Who are Bio-Rad Laboratories' major shareholders?: Bio-Rad Laboratories' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Polianta Ltd (0.01%), Park Avenue Securities LLC (0.01%), First Hawaiian Bank (0.01%), Insight Wealth Strategies LLC (0.00%), Fulton Bank N.A. (0.00%) and Ballentine Partners LLC (0.00%). Insiders that own company stock include Ajit Ramalingam, Annette Tumolo, Dara Wright, Ilan Daskal, Michael Crowley, Timothy S Ernst and Timothy S Ernst.
View institutional ownership trends.
How do I buy shares of Bio-Rad Laboratories?: Shares of BIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Bio-Rad Laboratories have any subsidiaries?: The following companies are subsidiares of Bio-Rad Laboratories: (f/k/a Bio-Rad Laboratories (Israel) Inc.), BIO-RAD spol. s r.o., Bio-Metrics (U.K.) Limited, Bio-Rad, Bio-Rad (Shanghai) Life Science Research & Development Co. Ltd., Bio-Rad 1, Bio-Rad AbD Serotec GmbH, Bio-Rad AbD Serotec Ltd, Bio-Rad China Ltd., Bio-Rad Denmark ApS, Bio-Rad Europe GmbH, Bio-Rad Export LLC, Bio-Rad Finland Oy (f/k/a DiaMed Fennica Oy), Bio-Rad France, Bio-Rad France Holding, Bio-Rad Germany Holding GmbH, Bio-Rad Haifa Ltd., Bio-Rad Holdings LLC, Bio-Rad Hungary Trading LLC, Bio-Rad IHC Europe GmbH, Bio-Rad Innovations, Bio-Rad Korea Ltd., Bio-Rad Laboratories (Canada) Limited, Bio-Rad Laboratories (India) Private Limited, Bio-Rad Laboratories (Pty) Ltd, Bio-Rad Laboratories (Rishon) Inc., Bio-Rad Laboratories (Shanghai) Co. Ltd., Bio-Rad Laboratories (Singapore) Pte Ltd, Bio-Rad Laboratories AB, Bio-Rad Laboratories AG, Bio-Rad Laboratories B.V., Bio-Rad Laboratories Ges.m.b.H., Bio-Rad Laboratories GmbH, Bio-Rad Laboratories K.K., Bio-Rad Laboratories Limited, Bio-Rad Laboratories Logistik GmbH, Bio-Rad Laboratories Ltd., Bio-Rad Laboratories M.EPE, Bio-Rad Laboratories NV, Bio-Rad Laboratories Pty Ltd, Bio-Rad Laboratories S.A., Bio-Rad Laboratories S.r.l., Bio-Rad Laboratories SAS, Bio-Rad Laboratories-Aparelhos e Reagentes para Laboratórios Lda, Bio-Rad Laboratorii OOO, Bio-Rad Laboratórios Brasil Ltda., Bio-Rad Luxembourg S.à r.l., Bio-Rad Medical Diagnostics GmbH, Bio-Rad Middle East FZ-LLC, Bio-Rad Norway AS, Bio-Rad Pacific Limited, Bio-Rad Pasteur, Bio-Rad Polska Sp. z o.o., Bio-Rad QL Inc., Bio-Rad S.A., Bio-Rad Services France, Bio-Rad Services UK Limited, Biotest - Businesses, Blackhawk Biosystems, Bridger Technologies Inc., Celsee, Ciphergen Biosystems - ProteinChip Systems Business, DiaMed (G.B.) Ltd, DiaMed (Schweiz) GmbH, DiaMed Benelux NV, DiaMed Diagnostika Deutschland GmbH, DiaMed France SA, DiaMed GmbH, DiaMed Holding AG, DiaMed Holding GmbH, DiaMed Latino-América S.A., DiaMed S.E.A. Limited, DiaMed Österreich GmbH, Distribudora de Analítica para la Medicina Ibérica S.A.U., Dropworks Inc., GnuBIO Inc., Helix Diagnostics, IMV Medical Information Division Inc., International Marketing Ventures Ltd., MJ GeneWorks, Propel Labs - Cell Sorting System Division, QuantaLife, Quantase Ltd., Raindance Technologies Limited, Raindance Techologies Inc., Research Specialties for Laboratories NV, Respiratory Diagnostics Inc., and Wuxi BioCanal Nano Technology Co. Ltd..
Read More

This page (NYSE:BIO) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Bio-Rad Laboratories (BIO) Stock Price, News & Analysis

Bio-Rad Laboratories MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Bio-Rad Laboratories Stock (NYSE:BIO)

BIO Stock Price History

BIO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

BIO Stock Analysis - Frequently Asked Questions

Overall MarketRank^™